Login
Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
HEALTH AND HUMAN SERVICES, DEPARTMENT OF has floated a tender for Cdrh-2024-122752-Add-On Senobright Hd with Nira Iq Suite Software for Ge Pristina Ffdm/Dbt System.. The project location is USA and the tender is closing on 05 May 2024. The tender notice number is FDA-RFQ-CDRH-2024-122752, while the TOT Ref Number is 100366715. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.
Procurement Summary
Country : USA
Summary : Cdrh-2024-122752-Add-On Senobright Hd with Nira Iq Suite Software for Ge Pristina Ffdm/Dbt System.
Deadline : 05 May 2024
Other Information
Notice Type : Tender
TOT Ref.No.: 100366715
Document Ref. No. : FDA-RFQ-CDRH-2024-122752
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Purchaser : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Contracting Office Address : Beltsville, MD 20705
Primary Point of Contact : Emmanuel T. Mbah
Emmanuel.mbah@fda.hhs.gov
Phone Number 2404027598
USA
Email :emmanuel.mbah@fda.hhs.gov
Tender Details
Description
The U. S. Food & Drug Administration, (FDA) Office of Acquisition and Grants Services (OAGS) has a requirement to procure a CDRH-2024-122752-Add-on SenoBright HD with Nira IQ suite software for GE Pristina FFDM/DBT System under Solicitation: FDA-RFQ-CDRH-2024-122752. The objective of the requirement is to procure the contrast-enhanced mammography software (SenoBright HD with Nira IQ suite) for the GE Senographe Pristina mammography system that will allow FDA researchers to develop and compare new methods for testing performance for this mode of mammography system. The end result of this requirement if the contract is successful will be the development of new approaches for objectively assessing image quality of contrast mammography systems. These new testing methods could potentially reduce the burden of sponsors that submit new technology to the FDA for approval and accelerate the introduction of new contrast mammography breast imaging products to the general public. New testing methods will be published as an OSEL regulatory science tool. See the attached RFQ for a response.
Active Contract Opportunity Notice ID FDA-RFQ-CDRH-2024-122752 Related Notice FDA-RFQ-CDRH-2024-122752 Department/Ind. Agency HEALTH AND HUMAN SERVICES, DEPARTMENT OF Sub-tier FOOD AND DRUG ADMINISTRATION Office FDA OFFICE OF ACQ GRANT SVCS
General Information
Contract Opportunity Type: Combined Synopsis/Solicitation (Original)
All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
Original Published Date: Apr 22, 2024 08:07 am EDT
Original Date Offers Due: May 05, 2024 12:00 pm EDT
Inactive Policy: 15 days after date offers due
Original Inactive Date: May 20, 2024
Initiative: None
Classification
Original Set Aside:
Product Service Code: AJ11 - General Science and Technology R&D Services; General science and technology; Basic Research
NAICS Code: 334516 - Analytical Laboratory Instrument Manufacturing
Place of Performance: Silver Spring, MD 20993 USA
Documents
Want To Bid in This Tender?
Get Local Agent Support in USA and 60 More Countries.
View Tenders By
Sign in with Google